A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-25

Study Completion Date

2022-06-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1b, open-label, multicenter study evaluating the safety and tolerability of ABT-199 in combination with rituximab in up to 50 subjects with Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. The primary objectives of this study are to assess the safety profile, to determine the maximum tolerated dose and establish the Recommended Phase Two Dose of ABT-199 when administered in combination with rituximab. The dose escalation portion of the study will include approximately 30 subjects. Once the recommended phase two dose and schedule have been determined, up to 20 additional subjects will be enrolled in an expanded safety portion of the study. Subjects who meet criteria for CR, CRi, or MRD-negative PR during the study may discontinue ABT 199. If disease progression occurs, as defined by iwCLL NCI/WG criteria for tumor response, or MRD progression, subjects may re-initiate ABT-199.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

NCT00788684

CD20-Positive Lymphoid Malignancies Chronic Lymphoid Leukemia Hematological Malignancies +1 more

COMPLETED PHASE1

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

NCT00406809

Chronic Lymphoid Leukemia Lymphoid Malignancies Non-Hodgkin's Lymphoma +3 more

COMPLETED PHASE1/PHASE2

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

NCT01087151

Chronic Lymphocytic Leukemia

COMPLETED PHASE2

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT01594229

Non-Hodgkin's Lymphoma

COMPLETED PHASE1

Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

NCT00286780

Chronic Lymphocytic Leukemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Small Lymphocytic Lymphoma Chronic Lymphocytic Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

Group Type EXPERIMENTAL

ABT-199

Intervention Type DRUG

ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.

Rituximab

Intervention Type DRUG

Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ABT-199

ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.

Intervention Type DRUG

Rituximab

Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

venetoclax

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject must be greater then or equal to 18 years of age.
* Subject must have relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
* Subject has an Eastern Cooperative Oncology Group performance score of less than or equal to 1.
* Subject must have adequate bone marrow independent of growth factor support per local laboratory reference range at Screening.
* Subject must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening.

Exclusion Criteria

* Chronic lymphocytic leukemia or Small Lymphocytic Lymphoma subject has undergone an allogeneic or autologous stem cell transplant.
* Subject has uncontrolled autoimmune hemolytic anemia or thrombocytopenia.
* Subject has tested positive for human immunodeficiency virus.
* Seropositivity for hepatitis B surface antigen or hepatitis C virus antibody or ribonucleic acid.
* History of severe allergic or anaphylactic reactions to rituximab.
* Subject has received a live viral vaccine within 6 months prior to the first dose of study drug.
* Subject has received a monoclonal antibody for anti-neoplastic intent within 8 weeks prior to the first dose of study drug.
* Subject has received any of the following within 14 days prior to the first dose of study drug, or has not recovered to less than grade 2 clinically significant adverse effect(s)/toxicity(s) of the previous therapy:

* Any anti-cancer therapy including chemotherapy, immunotherapy, or radiotherapy;
* Investigational therapy, including targeted small molecule agents.
* Subject has a cardiovascular disability status of New York Heart Association Class greater then or equal to 2. Class 2 is defined as cardiac disease in which subjects are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea or anginal pain.
* Subject has a significant history of renal, neurologic, psychiatric, pulmonary, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the investigator would adversely affect his/her participating in this study.
* Subject has a history of other active malignancies other than CLL/SLL within the past 2 years prior to study entry, with the exception of:

* Adequately treated in situ carcinoma of the cervix uteri;
* Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
* Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
* Subject has malabsorption syndrome or other condition that precludes enteral route of administration.
* Subject exhibits evidence of other clinically significant ongoing or recent condition(s) including, but not limited to:

* Ongoing systemic infection (viral, bacterial, or fungal);
* Diagnosis of fever and neutropenia within 1 week prior to study drug administration

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No